Provided by Tiger Fintech (Singapore) Pte. Ltd.

Telomir Pharmaceuticals

4.58
-0.4500-8.95%
Post-market: 4.590.0100+0.22%17:47 EDT
Volume:307.96K
Turnover:1.49M
Market Cap:136.31M
PE:-8.18
High:5.23
Open:5.10
Low:4.50
Close:5.03
Loading ...

Telomir Pharmaceuticals Inc - Telomir-1 Reverses Copper-Induced Ros Elevation in Human Cell Lines

THOMSON REUTERS
·
28 Jan

TELO Treatment Amazes in Preclinical Trial

Zacks Small Cap Research
·
28 Jan

Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) market cap surged US$16m last week, retail investors who have a lot riding on the company were rewarded

Simply Wall St.
·
16 Jan

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Zacks Small Cap Research
·
13 Jan

Renovaro Names Nathen Fuentes as CFO

MT Newswires Live
·
07 Jan

Telomir announces findings from preclinical progeria lifespan study

TIPRANKS
·
07 Jan

BRIEF-Telomir Pharmaceuticals Confirms Lifespan Restoration And Normalization Of Accelerated Aging In Preclinical Model Of Progeria

Reuters
·
07 Jan

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

ACCESSWIRE
·
07 Jan

Telomir Pharmaceuticals: Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria

THOMSON REUTERS
·
07 Jan

TELO Continues to Impress

Zacks Small Cap Research
·
07 Jan

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

ACCESSWIRE
·
23 Dec 2024

Telomir Pharmaceuticals- Confirms Copper-Binding Capabilities of Telomir-1, Expands Pipeline Into Wilson's Disease

THOMSON REUTERS
·
23 Dec 2024

Telomir Pharmaceuticals Inc - to Submit Ind & Inad Application by Q4 2025, With Clinical Trials Planned for 2026

THOMSON REUTERS
·
23 Dec 2024

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

Benzinga
·
23 Dec 2024

Telomir Pharmaceuticals Shares Down 12.57% at $4.45 in Premarket Trade; White Diamind Research Says It Has a Strong Sell Rating on the Stock

THOMSON REUTERS
·
13 Dec 2024

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

ACCESSWIRE
·
12 Dec 2024